Premium
Thyrotrophin‐Releasing Hormone Raises Cytosolic Free Calcium Concentration in Human Adenomatous Somatotrophs and Corticotrophs; Comparison with in vivo Responsiveness to Thyrotrophin‐Releasing Hormone in Patients with Acromegaly or Cushing's Disease
Author(s) -
Spada Anna,
RezaElahi Farzin,
Lania Andrea,
Pandiella Atanasio,
Bassetti Monique,
Bazzoni Nicoletta,
Alamo Paloma Gil,
Faglia Giovanni
Publication year - 1991
Publication title -
journal of neuroendocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.062
H-Index - 116
eISSN - 1365-2826
pISSN - 0953-8194
DOI - 10.1111/j.1365-2826.1991.tb00238.x
Subject(s) - corticotropic cell , endocrinology , medicine , somatotropic cell , acromegaly , in vivo , hormone , chemistry , growth hormone , biology , anterior pituitary , microbiology and biotechnology
The effect of thyrotrophin‐releasing hormone (TRH) on intracellular free Ca 2+ concentration, [Ca 2+ )i, was investigated with the fluorescent dye fura‐2 in cell suspensions obtained from 13 human growth hormone‐secreting adenomas and 6 adrenocorticotrophin‐secreting adenomas. Preoperatively, 9 out of 13 acromegalic patients showed a positive growth hormone response to TRH administration while none of the 6 patients with Cushing's disease had a plasma adrenocorticotrophin increase after TRH injection. In all the growth hormone‐secreting adenomas the addition of TRH (100 nM) caused a significant rise in [Ca 2+ ]i (from a resting level of 133±40 (±SD) to a value of 284±119 nM at 100 nM TRH, n = 42; P<0.001). The transient induced by TRH was found to have a dual origin, one due to Ca 2+ mobilization from intracellular stores which was maintained in presence of EGTA (3mM) and verapamil (10 μM) and a plateau phase due to Ca 2+ influx from the extracellular media. Somatostatin (0.1 μM) lowered both resting [Ca 2+ ]i and TRH‐induced transients. The effect of gonadotrophin‐releasing hormone on [Ca 2+ ]i was evaluated on cell suspensions obtained from 6 growth hormone‐secreting adenomas. Gonadotrophin‐releasing hormone (100 nM) caused a marked rise in [Ca 2+ ]i (from 179±25 to 283±15nM) on the cell suspension obtained from the only in vivo responsive adenoma while it was ineffective in the remaining 5. Although TRH was ineffective in modifying plasma adrenocorticotrophin levels in all patients with Cushing's disease, in 5 out of 6 tumors the addition of 100 nM TRH caused a significant rise in [Ca 2+ ]i (from 102.5 ± 36 to 163±66 nM, n = 22; P < 0.005). However, the effect of TRH on [Ca 2+ ]i was significantly lower than that caused by arginine vasopressin, a physiological stimulator of adrenocorticotrophin release ([Ca 2+ ]i values; 145±78 nM at 100 nM TRH versus 300±140 at 10 nM arginine vasopressin, n = 15; P<0.05). Moreover, the effect of arginine vasopressin on [Ca 2+ ]i was detectable at concentrations as low as 0.1 nM while TRH was effective at concentrations higher than 1 nM. By contrast, gonadotrophin‐releasing hormone was ineffective in increasing [Ca 2 ]i in all the adrenocorticotrophin‐secreting adenomas studied. Collectively, these data indicate that sensitivity to TRH is present in almost all the growth hormone‐ and adrenocorticotrophin‐secreting adenomas independently of the responsiveness of the individual patients to the peptide.